BIA today announces Blood Cancer UK as its charity partner of the year for 2025. This partnership demonstrates BIA’s commitment to driving meaningful change through collaboration.
Dr Mahony will work with the UK Government to champion investment into the UK’s innovative life sciences and biotech sector, including playing a key role in the ongoing pension reforms led by Chancellor Rachel Reeves MP.
BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.
Read our statement welcoming the Chancellor's recommitment to R&D tax credits, new funding initiatives, and sustained support for biotechnology and medical science.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
A new group of MPs and peers, with the support of the BioIndustry Association (BIA), has written to the Chancellor, urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget.
The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.
The Chancellor’s Budget on 30 October is an opportunity to end short-termism, cut waste, and attract long-term investment to the UK economy with a sector-targeted R&D tax relief policy. However, changes should not be rushed and must be based on the best economic evidence.
The UK Bioindustry Association (BIA) has today joined the European Biosolutions Coalition, adding UK representation to this influential group. The European Biosolutions Coalition is an initiative established by several industry organisations to elevate the prominence of biosolutions on the European agenda.
The Francis Crick Institute’s start-up accelerator KQ Labs and the UK Bioindustry Association (BIA) have launched a new programme to support growing companies working at the interface of biology and data technologies.
New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.
BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.
Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.
Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future.
Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.
New report highlights sector's strength, investor confidence and long-term returns
The UK’s innovative life sciences and biotech sector showed resilience in 2023, securing £1.8 billion in equity investment despite a challenging global economic climate, according to the latest report by the UK BioIndustry Association (BIA). London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.
The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.
